Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

E-ISSN： 1873-4286|19|29|5219-5238

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.29, 2013-09, pp. : 5219-5238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)

Current Drug Discovery Technologies, Vol. 4, Iss. 2, 2007-08 ,pp. : 133-140

Bentham Science Publishers

Access to resources Recommend Favorite

Methodologies for Investigating Natural Medicines for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 2, 2012-02 ,pp. : 278-291

Bentham Science Publishers

Access to resources Recommend Favorite

Functional diversity of the glutathione peroxidase gene family among human populations: implications for genetic predisposition to disease and drug response

By Polimanti Renato Fuciarelli Maria Destro-Bisol Giovanni Battaggia Cinzia

Pharmacogenomics, Vol. 14, Iss. 9, 2013-07 ,pp. : 1037-1045

Future Medicine

Access to resources Recommend Favorite

Genetic Predisposition to Parkinson’s Disease and Cancer

Current Cancer Drug Targets, Vol. 14, Iss. 3, 2014-03 ,pp. : 310-321

Bentham Science Publishers

Access to resources Recommend Favorite

Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 8, Iss. 4, 2008-12 ,pp. : 301-307

Bentham Science Publishers

Access to resources Recommend Favorite